Diovan HCT Related Published Studies
Well-designed clinical trials related to Diovan HCT (Valsartan / Hydrochlorothiazide)
Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. [2011.10.01]
Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. [2011.08]
Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. [2011.08]
Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy. [2010.12]
24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study. [2010.11]
Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. [2010.07]
Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in
patients with stage-1 or stage-2 hypertension. [2010]
Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. [2009.11]
Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. [2009.06]
Efficacy and safety of valsartan/hydrochlorothiazide fixed-dose combination compared with amlodipine monotherapy as first-line therapy for mild to moderate hypertension. [2009.03]
Clevidipine: a review of its use in the management of acute hypertension. [2009]
The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial. [2009]
Randomized, Double-blinded Trial Evaluation of Valsartan/Hydrochlorothiazide Combination Therapy in Mild to Moderate Essential Hypertension in North-east China. [2008.07]
Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. [2008.06]
Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. [2008.01.24]
[Therapeutic efficacy of valsartan and valsartan/HCTZ in mild to moderate hypertensive patients] [2007.08]
Aliskiren, an orally effective Renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. [2007.01]
Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. [2007.01]
Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. [2006.07]
A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. [2005.09]
Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. [2005.07]
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. [2005.05]
24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study. [2005.04]
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. [2004.06.19]
Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. [2004.06]
Effects of valsartan/hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients. [2004.05]
Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). [2004.04]
Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. [2003.12]
A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. [2003.11]
Pulse pressure responses in patients treated with Valsartan and hydrochlorothiazide combination therapy. [2003.09]
Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. [2003.05]
Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. [2002.01]
Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. [2001.11]
A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. [2001.09]
[Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring] [2001.08]
Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. [2001.07]
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy. [1999]
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy. [1999]
Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. [1998.12]
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. [1998.11.10]
Valsartan and atenolol in patients with severe essential hypertension. [1998.08]
Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. [1997.02]
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. [1997]
Well-designed clinical trials possibly related to Diovan HCT (Valsartan / Hydrochlorothiazide)
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic
combination therapy in obese, hypertensive African American and white patients. [2013]
A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. [2005.11]
Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. [2004.12]
Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study. [2004.09]
[Evaluation of different approaches to the treatment of arterial hypertension: combination treatment with low dose perindopril/indapamide versus sequential treatment of stepped-dose treatment] [2003.07]
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. [2003.07]
Effect of AT1 receptor blockade on endothelial function in essential hypertension. [2003.02]
AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. [2002.12]
A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations? [2002.11]
Other research related to Diovan HCT (Valsartan / Hydrochlorothiazide)
Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients. [2011.10]
Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: valvet primary results. [2011.10]
24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. [2011.10]
Valsartan plus hydrochlorothiazide: a review of its use since its introduction. [2011.08]
Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension. [2011.05]
24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan,
Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure
substudy. [2011]
Effect of valsartan, hydrochlorothiazide, and their combination on 24-h
ambulatory blood pressure response in elderly patients with systolic
hypertension: a ValVET substudy. [2011]
Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. [2010.12]
Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement. [2010.09]
[Medication of the month. Exforge HCT: combination of amlodipine besylate, valsartan and hydrochlorothiazide in a single tablet]. [2010.07]
Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide
combination compared with monotherapy. [2010]
Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy. [2009.09]
Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility. [2009]
Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. [2008.08]
Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial. [2008.03]
The Effect of Valsartan Compared to Valsartan/Hydrochlorothiazide on Plasma Levels of Cellular Adhesion Molecules: The Val-MARC Trial. [2007.10.08]
Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. [2007.10.02]
[Intensive blood pressure reduction in patients with increased cardiovascular risk with high-dose combination therapy of 160 mg valsartan plus 25 mg hydrochlorothiazide. Results of the MACHT II observational study] [2007.08]
Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. [2007.07]
Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. [2007.02]
Anagrelide: a review of its use in the management of essential thrombocythaemia. [2006]
Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. [2005.12]
Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers. [2005.05]
Valsartan-induced hematocrit changes in renal transplant patients. [2005.04]
Automated office and home phone-transmitted blood pressure recordings in uncontrolled hypertension treated with valsartan and hydrochlorothiazide. [2004.12]
[Episodes of depression with attempted suicide after taking valsartan with hydrochlorothiazide] [2003.11.28]
Pharmacological profile and clinical use of moexipril. [2003.09]
[Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives] [2003.03.14]
Anastrozole: in early breast cancer. [2002]
Valsartan: a novel angiotensin type 1 receptor antagonist. [2000.01]
Valsartan/hydrochlorothiazide. [1999.05]
Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats (SHR). [1998.01]
Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. [1997.08]
Other possibly related research studies
A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. [2005]
Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. [2005]
Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. [2005.01]
Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension. [2004.11]
Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. [2004.10]
Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. [2004]
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. [2004]
The sartans are coming! [2000.03]
Sexual activity in hypertensive men. [2003.08]
Gateways to Clinical Trials. [2002.09]
Gateways to clinical trials. [2002.05]
Telmisartan: a review of its use in hypertension. [2001]
Clinical differences among angiotensin II receptor antagonists. [2001]
Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. [2000.04]
Irbesartan: an updated review of its use in cardiovascular disorders. [2000.05]
Angiotensin II antagonists for hypertension: are there differences in efficacy? [2000.04]
|
